How Long Is PCP Detectable in a Urine Test?

PCP (phencyclidine) typically shows up on a standard urine drug screen for roughly one to seven days after a single use, but chronic or heavy use can stretch that window to several weeks and, in extreme cases, even longer. That wide range exists because PCP has an unusual relationship with body fat, and several personal factors shift the timeline substantially. The drug is one of only five substances mandated for federal workplace testing, so understanding what influences its detection window matters for anyone facing a screening.

The General Detection Window

For someone who uses PCP once or infrequently, most clinical references place the urine detection window at roughly one to seven days. If you used a moderate dose a single time, a standard immunoassay will usually come back negative within about a week. That estimate applies to people of average weight and health who are reasonably well hydrated.

Chronic users face a much longer timeline. Repeated PCP use leads to accumulation in fat tissue, and the drug trickles back into the bloodstream over days or weeks as the body mobilizes those fat stores. Heavy, long-term users have tested positive on urine screens for 30 days or more after their last dose. An unusual case involving law enforcement officers who were occupationally exposed to PCP while handling confiscated drug preparations found that one officer still had detectable PCP in blood and urine at least six months after the last known exposure.¹ That case is extreme and involved repeated dermal and inhalation exposure without protective equipment, but it illustrates how stubborn PCP can be once it settles into the body’s fat compartments.

Why PCP Lingers in the Body

PCP is highly fat-soluble, which is the main reason its detection window varies so dramatically from person to person. Animal research measuring PCP distribution after a single injection found that fat tissue concentrated the drug at 31 to 113 times the level found in blood plasma, and PCP and its metabolites persisted in adipose tissue for prolonged periods even after a single dose.² With repeated dosing, the drug accumulates further in those fat stores. This is why someone who uses PCP regularly carries a much larger reservoir of the drug than someone who tried it once.

The practical consequence is that anything causing the body to break down stored fat can release PCP back into circulation. Rapid weight loss, intense exercise, fasting, or severe stress could theoretically push a burst of stored PCP into the bloodstream and then into urine, potentially causing a positive test well after the last intentional use. This isn’t just theoretical hand-waving: the same animal data noted that food deprivation or marked weight loss raised the possibility of mobilizing large amounts of drug from fat stores.² For a chronic user trying to pass a drug test weeks later, a crash diet could actually work against them.

Once PCP does leave fat stores and enter the bloodstream, the liver breaks it down primarily through a family of enzymes that add oxygen-containing groups to the molecule. This process produces several water-soluble breakdown products that the kidneys can filter out.³ Some of these metabolites are further processed and paired with other molecules to make them even easier for the body to excrete. The rate at which your liver handles this chemistry depends on your individual enzyme activity, overall liver health, and genetics.

Urine pH Makes a Measurable Difference

PCP is a weak base, which means it behaves differently depending on how acidic or alkaline your urine is. When urine is more acidic, PCP becomes ionized (essentially trapped in its water-soluble form), so the kidneys excrete it faster. When urine is more alkaline, PCP stays in a form that can be reabsorbed back into the body, slowing elimination. Research administering small doses of radiolabeled PCP to healthy volunteers under conditions designed to acidify or alkalinize their urine confirmed that pH substantially altered how quickly PCP and its metabolites appeared in urine.⁴

This is why some older clinical protocols for PCP overdose included urinary acidification as a strategy to speed drug clearance. In practice, deliberate urinary acidification has largely fallen out of favor because the risks (kidney damage, metabolic complications) usually outweigh the benefits. But the underlying chemistry still matters for detection: a person whose diet or medications happen to keep their urine on the acidic side will clear PCP somewhat faster than someone with consistently alkaline urine. Hydration plays a role too, though mostly by diluting the concentration of PCP metabolites in any given urine sample rather than by genuinely speeding up total-body clearance.

What the Standard Urine Test Actually Detects

Most workplace and clinical urine drug screens use an immunoassay, which works by exposing the urine sample to antibodies designed to bind to PCP. If enough PCP or PCP-like molecules are present, the test triggers a positive result. The federal cutoff for a positive PCP screen is 25 nanograms per milliliter. Below that threshold, the test reads as negative even if trace amounts of PCP are technically present.

PCP is part of the standard five-panel test required by the Department of Health and Human Services for federal workplace screening.⁵ That means if you’re tested for a government job, a transportation role, or any employer following SAMHSA guidelines, PCP is automatically included alongside amphetamines, cannabinoids, cocaine, and opiates. Many private employers use the same five-panel, though some use expanded panels that add additional substances.

An important point that surprises many people: urine PCP levels do not reliably reflect how intoxicated someone is or was. A study of a thousand cases of acute PCP intoxication found that urine PCP concentrations did not correlate with the severity of clinical symptoms.⁶ Someone with a relatively low urine level could be in serious medical distress, while someone with a higher level might appear relatively stable. The test tells you whether PCP is present, not how impaired the person is or was.

Medications That Cause False-Positive PCP Results

One of the most frustrating aspects of PCP urine testing is that several common, entirely legal medications can produce a false positive. Because immunoassays rely on antibody binding rather than definitive molecular identification, structurally similar compounds can fool the test.

A study examining which medications were significantly more common among patients with false-positive PCP screens found that tramadol, dextromethorphan (the cough suppressant in many over-the-counter cold medicines), alprazolam, clonazepam, and carvedilol were all linked to false-positive results.⁷ Diphenhydramine (the active ingredient in Benadryl) also showed up more often in the false-positive group, though the association didn’t reach statistical significance in that study.

Venlafaxine, a widely prescribed antidepressant, is one of the best-documented causes of false-positive PCP screens.⁸ Its active metabolite, O-desmethylvenlafaxine, is also available as its own prescription medication (sold under brand names like Pristiq), and it too has been reported to trigger false-positive PCP results.⁹ If you take either of these antidepressants and face a drug test, it’s worth mentioning your prescription to the testing provider beforehand.

The fix for a false positive is a confirmation test, usually gas chromatography-mass spectrometry (GC-MS). This second-stage test identifies the exact molecule present in the sample rather than relying on antibody cross-reactivity, so it can distinguish PCP from venlafaxine or dextromethorphan with high accuracy. Federal workplace testing protocols require a confirmation test before any positive immunoassay result is reported as final. Not all clinical or private-sector tests follow that protocol automatically, though, so if you get a positive and haven’t used PCP, requesting GC-MS confirmation is the right move.

PCP Analogues and Cross-Reactivity

PCP itself is relatively rare in many drug markets today, but a family of related dissociative compounds has emerged in the last couple of decades. Substances like 3-MeO-PCP and 4-MeO-PCP are structural cousins of PCP, and whether they trigger a standard PCP urine test depends on the specific immunoassay kit being used. Testing across five different commercial PCP immunoassays found that 3-MeO-PCP and 4-MeO-PCP showed cross-reactivity in all five, ranging from about 1% to 143% depending on the assay and the analogue.¹⁰ That wide range means someone who used 3-MeO-PCP might test positive on one hospital’s screening kit and negative on another’s.

Methoxetamine (MXE), another dissociative that briefly gained popularity, showed only very weak cross-reactivity with PCP immunoassays. Ketamine, which is structurally more distant from PCP despite being in the same pharmacological family, was not detected by any of the five PCP immunoassays tested.¹⁰ So a positive PCP screen tells you something from the PCP family (or a false-positive culprit) is likely present, but it won’t reliably catch ketamine or MXE.

Sample Tampering and Specimen Integrity

People facing drug tests sometimes try to beat them by adulterating their urine samples. Common household adulterants include bleach, table salt, laundry detergent, toilet bowl cleaner, vinegar, lemon juice, and eyedrops. Most of these can be caught by routine specimen integrity checks that measure creatinine concentration, pH, temperature, and specific gravity.¹¹ A sample that’s too cold, too dilute, or has an impossible pH is flagged as suspicious.

Some commercially marketed adulterant products are harder to detect. A product called Stealth, for instance, did not cause urine samples to exceed any of the monitored parameters routinely used in drug-testing laboratories, including for PCP-spiked samples.¹² Labs have since developed additional oxidant-specific checks to catch products like these, but the cat-and-mouse game between adulterant manufacturers and testing laboratories continues. Observed collections, where someone watches you provide the sample, remain the most reliable countermeasure.

Passive Exposure and Secondhand Contact

A question that comes up in contested drug-test results is whether someone could test positive for PCP from being in the same room as someone smoking it. The honest answer is that the evidence barely exists. A review of the scientific literature on workplace drug testing noted that while passive inhalation of PCP is theoretically possible, no data were available to confirm or rule it out at the time of publication.¹³ Unlike marijuana, where secondhand smoke studies have been conducted (and generally show that passive exposure in normal ventilation doesn’t produce a positive test at standard cutoffs), the equivalent research just hasn’t been done for PCP. If someone claims a positive PCP result was caused by passive exposure, there’s essentially no published evidence to support or refute the claim.

Neonatal Detection After Prenatal Exposure

PCP crosses the placenta, and newborns exposed in utero face their own detection timeline. In cases of transplacental PCP transmission, infants’ urine has tested positive by immunoassay for up to eight days after birth, and more sensitive laboratory methods (gas chromatography and radioimmunoassay) have detected PCP for ten days.¹⁴ What was particularly striking is that the newborns continued to excrete detectable PCP even after the drug was no longer measurable in their blood, which suggests that significant body stores of PCP had built up during pregnancy. Infants lack the mature liver enzyme systems that adults rely on to break down drugs efficiently, so clearance takes longer relative to their body weight.

This matters clinically because PCP-exposed newborns can show signs of toxicity, and knowing how long the drug remains in the infant’s system helps neonatal care teams manage symptoms. It also means that meconium testing (which captures drug exposure over weeks to months of gestation) is sometimes preferred over urine testing when the question is whether prenatal exposure occurred at all, rather than how recently.

Individual Factors That Shift the Timeline

Putting the pieces together, several personal characteristics shorten or lengthen your PCP detection window beyond the “one to seven days” starting estimate:

• Body fat percentage: More fat tissue means a larger reservoir for PCP to hide in and a slower overall clearance.
• Frequency and dose: A single low dose clears faster than weeks of repeated use, which causes accumulation.
• Urine acidity: More acidic urine speeds renal excretion; more alkaline urine slows it.
• Hydration: Dilute urine lowers the concentration of PCP metabolites per milliliter, which can push a borderline result below the cutoff, though it won’t actually remove PCP from your body faster.
• Liver function: Since PCP is metabolized by liver enzymes, impaired liver function slows clearance.
• Age and metabolism: Younger, more metabolically active people tend to clear drugs faster than older adults, though this effect is modest compared to the impact of body fat and use history.

The single biggest determinant, by far, is how often and how much PCP you’ve used. An occasional user can reasonably expect a clean test within a week. A daily or near-daily user should plan for weeks, and in some cases a month or more, before levels drop below the screening cutoff. The occupational exposure case where PCP persisted for six months is an outlier, but it underscores that there is no hard ceiling on detection time when the body has accumulated enough of the drug.

Why Urine Levels Don’t Tell You Much Clinically

If you or someone you know is being evaluated in an emergency setting after suspected PCP use, it helps to know that a urine drug screen is a blunt instrument. As noted earlier, the concentration of PCP in urine does not predict how severe the intoxication is.⁶ Clinicians treat based on symptoms, not urine levels. Someone who tests negative but is clearly showing signs of dissociative intoxication will still be treated aggressively, while a positive result in someone who feels fine doesn’t trigger aggressive intervention on its own.

This disconnect exists partly because urine represents what the kidneys filtered out over a period of hours, not what’s circulating in the brain at that moment. A person could have high brain concentrations of PCP and relatively low urine levels early in an episode, or low brain concentrations and high urine levels later as the drug clears. Blood or serum levels provide a somewhat better snapshot of current intoxication, but even those correlate imperfectly with behavior and symptoms because PCP’s effects depend on receptor binding in the brain, not just the amount floating in the bloodstream.

PCP Metabolites Found in Urine

The standard immunoassay primarily targets the parent PCP molecule, but PCP also produces several metabolites that appear in urine. Research using gas chromatography-mass spectrometry has identified and quantified monohydroxy metabolites of PCP in urine, including the confirmation of 3-phenyl-3-(1-piperidinyl)-trans-cyclohexanol and the identification of a newer metabolite, 1-phenyl-1-(1-piperidinyl-3-ol)cyclohexane.¹⁵ These metabolites matter because some immunoassay kits cross-react with them to varying degrees, which means that even after the parent drug has been cleared, lingering metabolites could theoretically contribute to a positive screen. In confirmation testing, labs can distinguish between PCP itself and its breakdown products, giving a clearer picture of whether the person used PCP recently or is still excreting residual metabolites from an older exposure.